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Summary
Cell therapy in the form of human islet transplant-
ation has been a successful form of treatment for
patients with type 1 diabetes for over 10 years, but
is significantly limited by lack of suitable donor ma-
terial. A replenishable supply of insulin-producing
cells has the potential to address this problem; how-
ever to date success has been limited to a few
preclinical studies. Two of the most promising strate-
gies include differentiation of embryonic stem cells
and induced pluripotent stem cells towards insulin-
producing cells and transdifferentiation of acinar or
other closely related cell types towards b-cells. Here,
we discuss recent progress and challenges that need
to be overcome in taking cell therapy to the clinic.
Introduction
It is just over 90 years since J.J.R. Macleod and his
team at the University of Toronto discovered insu-
lin.1 The first patient, Leonard Thompson, at the
time of treatment was on a starvation diet that
was intended to extend his life for a few years.
He was injected with a crude extract of bovine
pancreas in January 1922 with an almost immedi-
ate effect on his glycosuria, blood glucose levels
and general well-being. From that moment
onward diabetes was no longer a fatal disease.
Since then, injection of exogenous insulin has
been in the vanguard in the battle to control the
disease; the aim being to simulate the normal pat-
tern of insulin secretion as closely as possible. This
has been best achieved by basal-bolus therapy
using multiple daily injections or continuous sub-
cutaneous insulin infusion pumps. There have been
many major breakthroughs since 1922, but none
more important than the cloning and sequencing
of the insulin gene in 1980,2 which brought
about the introduction of unlimited supplies of bac-
terially expressed human insulin and the technol-
ogy to modify the structure of the protein, such that
there are now at least six rapid-acting or long-
acting analogues. Combined with advances in glu-
cose monitoring, these modified insulins have
allowed patients to control their blood glucose
levels within relatively narrow limits. Achieving
tight glycaemic control with current medical ther-
apy is, however, something of a double-edged
sword. It has led to a fall in the microvascular com-
plications namely retinopathy, nephropathy and
neuropathy, reducing patient morbidity, but at a
consequence of increased rates of disabling hypo-
glycaemia. With diabetes now reaching epidemic
proportions affecting around 6% of the adult popu-
lation in the UK, and type 1 diabetes (T1D) ac-
counting for 5–10% of all cases, new therapeutic
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strategies are clearly required to reduce this colos-
sal health and economic burden.
Along with improvements in insulin therapy there
have been huge advances in our understanding of
the disease. T1D is an autoimmune disorder in
which activated CD4+ and CD8+ T lymphocytes
infiltrate the islets of Langerhans and selectively des-
troy the b-cells. Diagnosis is typically during child-
hood but can occur at any age, by which time
70–80% of the b-cell mass is already lost through
apoptosis. The cure for T1D is likely to come from
immune interventions directed at preventing the dis-
ease prior to the establishment of autoimmunity.3
For those people with established T1D progress
has been made in identifying targets for vaccines,
but there have been major challenges in establishing
realistic end-points for immunotherapeutic trials.4 In
the meantime improved insulin therapy, with em-
phasis on closed loop delivery systems or islet trans-
plantation, is generally accepted as the best way
forward. A comparison of continuous glucose moni-
toring data from patients on closed loop delivery
systems and those that have undergone islet trans-
plants indicates that current closed loop delivery
systems cannot get close to matching the control
that can be achieved by islet transplantation.
Current cell therapy
Islet transplantation mainly in the context of syn-
geneic transplantation following removal of the pan-
creas in patients with pancreatitis has been around
since the early 1990s.5 The success rate for syngeneic
islet transplants has been relatively good, but allo-
geneic transplantation of donor islets for the treat-
ment of T1D was plagued from the outset with poor
success rates; 8% graft function after 1 year. This
changed with the introduction of the Edmonton
Protocol in 2000, which placed emphasis on trans-
planting a sufficiently large number of islets (typically
2–3 donors), minimizing the cold ischemia time and
implementing an immunosuppressive regimen with-
out corticosteroids.6 With further improvements in
immunosuppression, clinical islet transplantation
has progressed considerably such that by the end of
2013 over 750 patients with T1D have received
transplants. The 1-year success rates are high particu-
larly with regards to reduction in severe hypogly-
caemia, although there are still concerns about graft
failure with time.5 If advances could be made in ad-
dressing the allo- and auto-immune islet attack in the
recipient, then the procedure could be made more
widely available for patients with T1D. However,
before this can be envisaged there is a requirement
for a replenishable supply of islets that is not
dependent on cadaveric tissue. This brief review
will describe how progress in stem cell research has
been channelled towards this goal with emphasis on
our own experience in the differentiation of pluripo-
tent cells and the reprogramming of adult tissue.
Future cell therapy
Differentiation of pluripotent cells
towards b-cells
Pluripotent cells can be obtained from the inner cell
mass of pre-implantation embryos [embryonic stem
cells (ESCs)] or from the reprogramming of adult tis-
sues to generate induced pluripotent stem cells
(iPSCs). Mouse ESCs have been around since the
early 1980s.7,8 Human ESCs differ significantly
from mouse ESCs, probably because they arise
from a later stage in the developing blastocoel that
is more closely related to the mouse epiblast than
the inner cell mass of the fertilized egg.9 They re-
quire very different culture conditions and this in
part explains the lengthy time period between the
derivation of the first mouse and human ESCs in
1998.10 Since then around 800 human ESC lines
have been generated, although they vary markedly
in their quality and only a very small proportion of
these are in common use. iPSCs were first generated
from mouse embryonic and adult fibroblasts follow-
ing transduction with retroviruses containing four
transcription factors, Oct4, Sox2, Klf4 and c-Myc
that are normally expressed in ESCs.11 It was very
quickly established that iPSCs could be generated
from a variety of adult human cell types.12 In
common with ESCs iPSCs can theoretically be
induced to differentiate into any of the 200 or so
cell types in the body, and thus like ESCs have the
potential to provide an essentially unlimited supply
of specific cell types for basic research and trans-
plantation therapies for disease.
In terms of providing a replenishable supply of
islets for transplantation, it is likely that a small
number of pluripotent lines will be employed. The
reason for this is that each cell line would need to be
generated, maintained, and differentiated under
clinical GMP-grade conditions and expanded to
meet demand. A healthy pancreas contains about
1 million islets and an average-sized islet contains
a few hundred b-cells. This suggests that something
like 1 billion differentiated cells would be required
for each transplant. At clinical presentation most
people with T1D have some (10%) residual
b-cell function, suggesting that the bar could be
lowered. Nonetheless, this would still require cell
culture on an industrial scale, which could only be
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carried out by commercial companies that are
skilled in handling cell factories, as presently used
for the production of therapeutic monoclonal anti-
bodies. At present, there are a handful of ESC lines
that would fit these requirements. However, in the
future, there is a case for generating a bank of pluri-
potent cells selected on the basis of their growth,
differentiation capabilities and HLA-type. Islet trans-
plant recipients are not usually HLA-matched with
donors. However, despite being immunosup-
pressed, there is evidence that HLA-matching
would provide benefits from at least partial HLA-
matching.13 The ideal pluripotent stem cell bank
should therefore be sufficiently large to cover the
range of MHC compatibility within regional or
racial genetic backgrounds.14 For ESCs this would
involve screening an enormous range of lines from
embryos harvested from young women, a procedure
which is not without risk to the donor, and which
raises considerable ethical issues. iPSCs on the other
hand can be generated from easily accessible adult
tissues with little or no risk to the donor. iPSCs gen-
erated from specific patients could have the poten-
tial to provide insights into disease mechanisms;
however, in terms of cell therapy a limited number
of MHC-specific iPSC lines could be generated from
tens of thousands of donors and further selected on
the basis of their growth characteristics and ability to
differentiate down endoderm, mesoderm or ectoder-
mal lineages.15
Although ESCs and iPSCs share marked similari-
ties, there are subtle genomic differences within the
two populations and between these and
non-pluripotent cells.16 The origin of the genomic
alterations in iPSCs can be attributed to their pre-
existence in the parental somatic cells or their
acquisition during reprogramming. Culture adapta-
tions can also contribute to these defects for both
ESCs and iPSCs.17 However, the functional conse-
quences of these genomic aberrations, which for the
most part are epigenetic, i.e. do not involve changes
in DNA sequence, are not known. Epigenetic
changes may even have a positive effect on the
differentiation potential of iPSCs. At this stage, the
advantages that iPSCs provide in terms of generating
an autologous bank of HLA-typed pluripotent cells
likely outweigh any unknown consequence that epi-
genetic abnormalities (some of which are shared
with ESCs) might have on their clinical utility.
Considerable progress has been made in develop-
ing protocols for the efficient differentiation of pluri-
potent cells towards functional islets (Figure 1A).
The strategy is influenced by advances in under-
standing the mechanism that control pancreatic de-
velopment in the mouse.18 The first step (2 days,
D0–D2) is to induce formation of definite endoderm
by including high concentrations (100 ng/ml) of acti-
vin A in the culture media. Activin A mimics the
effects of nodal signalling in the early embryo.
The next stage (D2–D4) involves specification of
the pancreas, which is achieved by adding retinoic
acid and inhibiting endogenous sonic hedgehog sig-
nalling with cyclopamine. Formation of the pancre-
atic cell types is then achieved by adding fibroblast
growth factor (FGF) and inhibiting the actions of
activin A (D4–D6), which at this stage would push
the cells towards liver lineages.19 Inhibiting Delta/
Notch signalling (D7–D9), by use of a g-secretase
inhibitor, results in an enriched population of endo-
crine progenitors. To date, it has not been possible
to differentiate these progenitors further into fully
functional b-cells;20 however when placed under
the kidney capsule or epididymal fat pad of im-
munocompromised mice, the progenitors, after 12
weeks or so, secrete human C-peptide in a manner
that responds to a glucose tolerance test and can
rescue hyperglycaemia if the mice are subsequently
treated with streptozotocin, which kills mouse but
not human b-cells.19–21 These findings, including
variations of this blueprint, have been reproduced
in a number of laboratories, and at this stage pro-
posals are being drafted to take islet progenitors into
clinical trials. The plan would be to microencapsu-
late the progenitor cells in devices similar to those
produced by TheracyteTM,22,23 where maturation to
functional b-cells would take place. Encapsulation is
particularly important for safety reasons so that at
the first sign of any mal-function, the graft can be
removed. The ideal microencapsulation device
would also act as an immunobarrier. It is important
to note that newly diagnosed T1D patients with re-
sidual C-peptide at the lower end of the normal
range (73pM) exhibit a good response to a
mixed meal tolerance test. So even producing
small amounts of insulin would have a beneficial
effect not only in terms of glycaemic control but
also with respect to reducing fear of hypoglycaemia.
Reprogramming adult cell types towards
b-cells
The idea that one differentiated human cell type
could be converted into another would have been
met with ridicule not so many years ago.24 There
was evidence that some cells could transdifferenti-
ate during embryogenesis or under highly specific
circumstances, but this was not a property generally
associated with differentiated tissues. However, the
ground-breaking work of Takahashi and Yamanaka,
showing that essentially any tissue could be repro-
grammed towards pluripotent cells, i.e. iPSCs, revo-
lutionized the concept of tissue plasticity.11 Prior to
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this there were data around showing that exocrine
pancreatic cells could be induced to transdifferenti-
ate into b-like cells,25 whereas overexpression of
pancreatic transcription factors in the liver of
frogs26 and mice27 could induce formation of pan-
creatic cell types. However, post-Yamanaka, re-
searchers could think realistically about deriving
b-cells from adult tissue. In terms of technical chal-
lenges, it would be easier to generate b-cells from
cells that were developmentally more closely
related; these would include liver and pancreatic
exocrine tissue.28 As it turns out during the islet iso-
lation procedure the bulk (98%) of the pancreas is
discarded. What if this material could be repro-
grammed into b-cells? As each recipient requires
up to three islet grafts, this would provide a donor-
specific replenishable supply. The ability to perform
multiple grafts using reprogrammed cells from a
single recipient rather than depending on islet cells
from multiple donors would be advantageous from
an immune-tolerance stand-point.13,29 Moreover,
the reprogrammed cells could be cryopreserved
and made available as a recipient-specific top-up
supply of islets as the function of the original graft
deteriorates over time.
Some progress has been made. When placed in
culture, the exocrine material, which is enriched in
acinar and ductal cells along with passenger stromal
cells and blood vessel-derived cells, attaches to the
dish and undergoes a process of dedifferentiation to
form a fibroblast-like monolayer that can be repeat-
edly passaged.30,31 These fibroblasts express surface
markers characteristic of mesenchymal stromal cells
(MSCs), and in keeping with the properties of MSCs
they can be induced to differentiate along adipo-
cyte, osteoblast and chondrocyte lineages. Genetic
lineage tracing combined with immunocyto-
chemistry suggests that these MSCs arise in part
from amylase- and insulin-expressing cells through
a process of epithelial-to-mesenchymal transitioning
(EMT).32,33 When cultured in low serum in the
presence of growth factors such as glucagon-like
peptide 1 (GLP-1) or its analogues, these MSCs
can be induced to redifferentiate into cells that ex-
press insulin and share some of the properties of b-
cells.34,35 These redifferentiated cells have been
shown to lower blood glucose levels when engrafted
into streptozotocin-diabetic mice,34 although the ef-
ficiency of the process and the resultant levels of
insulin are very low.35 An alternative approach is

































Figure 1. Strategies for generating a replenishable supply of beta cells. (A) Schematic representation of the stepwise differ-
entiation of pluripotent cells towards b-cells in vitro. The final maturation stages of beta cell development remain challenging
to replicate under in vitro conditions. (B) Procedure for reprogramming the exocrine tissue resultant from the islet isolation
procedure towards functional beta cells. After being placed in culture, the exocrine phenotype is maintained by inhibiting
EMT. Reprogramming towards functional beta cells is subsequently achieved by overexpression of pancreatic transcription
factors and growth factors.
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to force overexpression of pancreatic transcription
factors such as Pdx1, Ngn3, MafA and Pax4 in com-
bination with growth factors and reagents that are
known to modify chromatin structure33 (Figure 1B).
When this strategy was applied to exocrine-derived
MSCs the resulting cells were predominantly a-like,
expressing high levels of glucagon but very little in-
sulin. The key to generating a population enriched
in b-cells was to use freshly cultured exocrine ma-
terial and block EMT with rho-associated protein
kinase (ROCK) and transforming growth factor b1
(TGFB1) inhibitors. The resultant cells secreted insu-
lin in response to changes in glucose levels in the
physiological range and reversed hyperglycaemia
when grafted into immune-deficient streptozotocin-
induced diabetic mice.33
Conclusion
Considerable progress has been made in deriving
b-like cells from pluripotent stem cells or through
reprogramming of adult pancreatic exocrine tissue.
Islet progenitors can be reproducibly generated from
human ESCs and iPSCs and it is envisaged that these
progenitors may have clinical utility, and that a bank
of HLA-typed iPSCs would be used as a source of
material. The differentiated progenitors would be
encapsulated and grafted subcutaneously into pa-
tients. The expectation is that following engraftment
they would mature into functional b-cells.
Transcription factor-mediated reprogramming of
exocrine tissue is viewed at present as a patient-spe-
cific procedure. This approach has the advantage
that the cells would be processed under clinical
GMP-grade facilities adjacent to the islet isolation
facility. With efficient protocols, there would be no
requirement for large scale expansion of the cells as
the exocrine tissue would provide adequate material
for subsequent transplants to the original recipient.
However, if some of the technical hurdles could be
overcome, then the MSCs generated from the exo-
crine tissue, or indeed endocrine tissue, could be
expanded several hundred thousand-fold, and sub-
sequently redifferentiated to provide HLA-typed
banks of cells for allogeneic transplantation.36
Finally, it is worth noting that the default pathway
when differentiating pluripotent cells or reprogram-
ming adult exocrine cells is towards the formation of
glucagon-secreting a-cells.33,37 It is well established
that glucagon secretion in T1D is impaired, and
there is further strong evidence from closed loop
delivery systems that bi-hormonal delivery of insulin
and glucagon has been shown to reduce the risk of
hypoglycaemia when compared with delivery of
insulin alone.38 From a cell therapy perspective, it
may be less challenging to make the two cell popu-
lation separately and combine these to generate a-
and b-cell enriched islet-like structures than attempt
to generate a functional islet ab initio.
From a translational perspective, transplantation of
insulin-producing cells is only likely to become a
widely adopted therapeutic strategy with significant
advances in circumventing immune rejection of the
transplanted cells. At present, islet transplantation is
only offered to those where the benefits of treatment,
i.e. prevention of disabling hypoglycaemia, outweigh
the risks of lifelong immunosuppression. Even if
donor material was unlimited, the safest way of
managing T1D would remain exogenous insulin ther-
apy for the majority. Immunomodulation and immu-
noisolation are two ways whereby transplanted cells
could be protected from immune rejection by the
host. Immunomodulation, which involves altering
the host immune response, could come in the form
of modified regimens using available agents or from
more novel strategies.39 Immunoisolation would
allow transplanted cells to obtain adequate nutrients
and secrete insulin in a glucose-dependent manner
whilst preventing their allo- or auto-immune rejec-
tion. Perhaps, the best example of success is
described in a recent study40 where a patient was
treated with encapsulated islets maintained within
an oxygenated chamber. The implanted cells re-
mained glucose responsive at 10 months despite no
immunosuppression.
With these advances in generation of insulin-pro-
ducing cells in vitro and parallel progress in preven-
tion in immune rejection, we are now closer than
ever towards providing a cell-based solution to
patients with T1D.
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